Diagnostic and Therapeutic Strategies for the Management of Acquired Hemophilia A

Click the “Start Program” button to indicate you have reviewed the CME/CE information for this activity.
Start Program


Release Date: June 24, 2016
Expiration Date: June 24, 2017
Estimated Time to Complete Activity: 30
Minimum System Requirements:
  • Internet Explorer 7 (or higher)
  • Mozilla Firefox 4 (or higher)
  • Google Chrome (latest version)
  • Adobe Acrobat 6.0 (or higher)
  • Screen resolution 1024 x 768
Click here to contact Postgraduate Institute for Medicine (PIM)
Target Audience
This activity is designed to meet the needs of physicians, registered nurses, and other healthcare providers involved in the care of patients with acquired bleeding disorders.

Statement of Need/Program Overview
The rarity of acquired hemophilia A (AHA) has resulted in a lack of awareness among clinicians, and this potentially life-threatening bleeding diathesis may go unrecognized. Although the two-fold objectives of treating AHA are clear—to control bleeding and remove the inhibitor—management is complex and often challenging. Diagnosis may be delayed, and AHA may be mistaken for congenital or other acquired bleeding disorders. The etiology of AHA is frequently unexplained and the bleeding presentation can be highly variable. Nevertheless, prompt recognition and management are crucial because mortality rates may be as high as 22%, especially early in the disease. Recent reviews of the management of AHA have recognized clinical practice gaps and the need for education in the timely recognition and evidence-based therapy of AHA. In this activity, expert faculty will discuss the differential diagnosis, laboratory findings, appropriate treatment, inhibitor eradication, safety concerns, and the need for long-term monitoring in AHA.

Educational Objectives
After participating in this activity, participants should be able to:
  • Describe the laboratory differential diagnosis of AHA
  • Apply current strategies in the hemostatic treatment of patients with AHA
  • Employ recommended regimens for immunosuppressive therapy in patients with AHA
Presenting Faculty
Miguel A. Escobar, MD
Professor of Medicine and Pediatrics
Department of Hematology
University of Texas Health Science Center and MD Anderson Cancer Center
Medical Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Physician Continuing Medical Education
ACCME Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and CMEology. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Credit Designation
This educational activity for 0.5 contact hours is provided by Postgraduate Institute for Medicine.

ANCC Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty has reported the following financial relationships or relations they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Faculty or Presenter Reported Financial Relationship
Miguel A. Escobar, MD Consulting fees: Baxalta, Bayer, Kedrion Biopharma, LFB, Novo Nordisk, Pfizer Inc

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. The following CMEology planners and managers, Sylvie Laflamme, Rob Lowney, and Dana Ravyn, PhD, MPH, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Method of Participation
During the period of June 24, 2016, through June 24, 2017, participants must:
  • Read the learning objectives and faculty disclosures
  • Study the educational activity
  • Complete the posttest by recording the best answer to each question
  • Complete the evaluation form
A statement of credit will be issued automatically upon successfully completing the posttest with a score of 75% or better and submitting the activity evaluation.

Media
Internet

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.